

Riina Richardson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2908196/publications.pdf>

Version: 2024-02-01

65
papers

3,312
citations

236925

25
h-index

155660

55
g-index

67
all docs

67
docs citations

67
times ranked

4189
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	6.0	133
2	A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL). <i>Thorax</i> , 2022, 77, 821-828.	5.6	15
3	An overview of using fungal DNA for the diagnosis of invasive mycoses. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 169-184.	3.1	18
4	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 827-840.	4.0	13
5	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0229821.	3.9	17
6	Prevalence of bacteraemia following dental extraction—efficacy of the prophylactic use of amoxicillin and clindamycin. <i>Acta Odontologica Scandinavica</i> , 2021, 79, 25-30.	1.6	6
7	Expression of p53 is associated with microbial acetaldehyde production in oral squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 527-533.	0.4	4
8	Talaromycosis in a renal transplant recipient returning from South China. <i>Transplant Infectious Disease</i> , 2021, 23, e13447.	1.7	6
9	Molecular Epidemiology of <i>Aspergillus fumigatus</i> in Chronic Pulmonary Aspergillosis Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 152.	3.5	5
10	Impact of airway <i>Exophiala</i> spp. on children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 702-707.	0.7	4
11	Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom Biofilm Disease of <i>Candida</i> and <i>Lactobacillus</i> . <i>MSystems</i> , 2021, 6, e0062221.	3.8	35
12	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
13	Effectiveness of D,L-2-hydroxyisocaproic acid (HICA) and alpha-mangostin against endodontopathogenic microorganisms in a multispecies bacterial–fungal biofilm in an <i>ex vivo</i> tooth model. <i>International Endodontic Journal</i> , 2021, 54, 2243-2255.	5.0	7
14	Antibacterial Activity of 2-Hydroxyisocaproic Acid (HICA) Against Obligate Anaerobic Bacterial Species Associated With Periodontal Disease. <i>Microbiology Insights</i> , 2021, 14, 117863612110500.	2.0	7
15	The Fungal PCR Initiative's evaluation of in-house and commercial <i>Pneumocystis jirovecii</i> qPCR assays: Toward a standard for a diagnostics assay. <i>Medical Mycology</i> , 2020, 58, 779-788.	0.7	39
16	High-volume culture and quantitative real-time PCR for the detection of <i>Aspergillus</i> in sputum. <i>Clinical Microbiology and Infection</i> , 2020, 26, 935-940.	6.0	52
17	Biotic Environments Supporting the Persistence of Clinically Relevant Mucormycetes. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 4.	3.5	26
18	Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115124.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	17
20	Deciphering <i>Aspergillus fumigatus</i> cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3501-3509.	3.0	9
21	British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). <i>International Journal of STD and AIDS</i> , 2020, 31, 1124-1144.	1.1	20
22	Absence of Azole Antifungal Resistance in <i>Aspergillus fumigatus</i> Isolated from Root Vegetables Harvested from UK Arable and Horticultural Soils. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 208.	3.5	6
23	Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 997-1003.	1.4	16
24	European confederation of medical mycology expert consultâ€”An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	4.0	8
25	Detecting Azole-Antifungal Resistance in <i>Aspergillus fumigatus</i> by Pyrosequencing. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 12.	3.5	19
26	Positive <i>Aspergillus</i> PCR as a marker of azole resistance or subâ€”therapeutic antifungal therapy in patients with chronic pulmonary aspergillosis. <i>Mycoses</i> , 2020, 63, 376-381.	4.0	4
27	Consensus-based antimicrobial resistance and stewardship competencies for UK undergraduate medical students. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa096.	2.1	6
28	Evaluation of risk factors for oral infection with potential for spread in a 1-year cohort study. <i>Clinical Oral Investigations</i> , 2019, 23, 905-911.	3.0	2
29	ECMM <i>Candi</i> Regâ€”A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	4.0	19
30	National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice. <i>Journal of Infection</i> , 2019, 79, 167-173.	3.3	27
31	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	5.8	123
32	Exposure to <i>Aspergillus</i> in Home and Healthcare Facilitiesâ€”Water Environments: Focus on Biofilms. <i>Microorganisms</i> , 2019, 7, 7.	3.6	31
33	Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. <i>Mycoses</i> , 2019, 62, 217-222.	4.0	20
34	Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1056-1061.	3.0	11
35	Electrical stimulation disrupts biofilms in a human wound model and reveals the potential for monitoring treatment response with volatile biomarkers. <i>Wound Repair and Regeneration</i> , 2019, 27, 5-18.	3.0	20
36	Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. <i>Medical Mycology</i> , 2019, 57, 133-150.	0.7	152

#	ARTICLE	IF	CITATIONS
37	Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876618.	3.2	6
38	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUALity of Clinical Candidaemia Management. <i>Mycoses</i> , 2018, 61, 326-330.	4.0	60
39	Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3488-3495.	3.0	31
40	Global burden of recurrent vulvovaginal candidiasis: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e339-e347.	9.1	334
41	Transcriptome Assembly and Profiling of <i>Candida auris</i> Reveals Novel Insights into Biofilm-Mediated Resistance. <i>MSphere</i> , 2018, 3, .	2.9	151
42	Validation of biofilm formation on human skin wound models and demonstration of clinically translatable bacteria-specific volatile signatures. <i>Scientific Reports</i> , 2018, 8, 9431.	3.3	55
43	Cutaneous wound biofilm and the potential for electrical stimulation in management of the microbiome. <i>Future Microbiology</i> , 2017, 12, 337-357.	2.0	13
44	Predictors of mortality in chronic pulmonary aspergillosis. <i>European Respiratory Journal</i> , 2017, 49, 1601062.	6.7	120
45	First isolation of the pan-azole-resistant <i>Aspergillus fumigatus</i> cyp51A TR46/Y121F/T289A mutant in a UK patient. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 512-514.	2.5	12
46	High level of β -D-glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 316-321.	1.8	9
47	Volatile organic compound detection as a potential means of diagnosing cutaneous wound infections. <i>Wound Repair and Regeneration</i> , 2017, 25, 574-590.	3.0	26
48	The global problem of antifungal resistance: prevalence, mechanisms, and management. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e383-e392.	9.1	670
49	621 Novel diagnostic approach in detecting skin infection: Identification of bacterial-specific volatile organic compounds in bacterial biofilms on human cutaneous wound models. <i>Journal of Investigative Dermatology</i> , 2017, 137, S107.	0.7	1
50	Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant <i>Candida auris</i>. <i>Emerging Infectious Diseases</i> , 2017, 23, 328-331.	4.3	296
51	TLR1-10, NF- κ B and p53 expression is increased in oral lichenoid disease. <i>PLoS ONE</i> , 2017, 12, e0181361.	2.5	16
52	Clinical oral microbiology: A view of the road ahead. <i>Faculty Dental Journal</i> , 2016, 7, 82-85.	0.2	0
53	Microbiology of Root Canal Infections. <i>Primary Dental Journal</i> , 2016, 5, 84-89.	0.6	62
54	Antimicrobial resistance: Antibiotics and consultant oral microbiologist posts. <i>British Dental Journal</i> , 2016, 220, 2-3.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Periodontal Disease and Late-Onset Aortic Prosthetic Vascular Graft Infection. Case Reports in Vascular Medicine, 2015, 2015, 1-3.	0.2	5
56	Management of severe acute dental infections. BMJ, The, 2015, 350, h1300-h1300.	6.0	36
57	A Novel Antifungal Is Active against <i>Candida albicans</i> Biofilms and Inhibits Mutagenic Acetaldehyde Production In Vitro. PLoS ONE, 2014, 9, e97864.	2.5	31
58	dl-2-Hydroxyisocaproic Acid Attenuates Inflammatory Responses in a Murine <i>Candida albicans</i> Biofilm Model. Vaccine Journal, 2014, 21, 1240-1245.	3.1	30
59	2-Hydroxyisocaproic acid is fungicidal for <i>Candida</i> and <i>Aspergillus</i> species. Mycoses, 2014, 57, 214-221.	4.0	47
60	The role of unfinished root canal treatment in odontogenic maxillofacial infections requiring hospital care. Clinical Oral Investigations, 2013, 17, 113-121.	3.0	25
61	Production of carcinogenic acetaldehyde by <i>Candida albicans</i> from patients with potentially malignant oral mucosal disorders. Journal of Oral Pathology and Medicine, 2013, 42, 243-249.	2.7	79
62	Candidacidal effect of fluconazole and chlorhexidine released from acrylic polymer. Journal of Antimicrobial Chemotherapy, 2013, 68, 587-592.	3.0	11
63	2-Hydroxyisocaproic acid (HICA): a new potential topical antibacterial agent. International Journal of Antimicrobial Agents, 2012, 39, 539-540.	2.5	33
64	Oral candidosis – Clinical challenges of a biofilm disease. Critical Reviews in Microbiology, 2011, 37, 328-336.	6.1	153
65	Quality control for diagnostic oral microbiology laboratories in European countries. Journal of Oral Microbiology, 2011, 3, 8395.	2.7	3